Most Viewed: Last TWO YEARS
  • Review|Open Access

    Role of natural antioxidants in the therapeutic management of hepatocellular carcinoma

    Hanaa Ali Hassan , Nermin E. El-Gharib , Anmar F. Azhari
    Hepatocellular carcinoma (HCC) is a growing health problem in humans. HCC is considered the most common of internal malignancy which cause the death of human, but in the developed Western world, HCC is less common accompanied by increasing essentially in incidence, due to it occurs specially in chronic liver disease. HCC associated with various risk factors including hepatitis B virus infection; hepatitis C virus infection; prolonged aflatoxin exposure; and alcoholic cirrhosis. Overall, one-third of cirrhosis patients will develop HCC during their life time. Also, chemical carcinogens cause... Read more
    Hepatoma Res 2016;2:216-23. | doi:10.20517/2394-5079.2016.12
    Published on: 5 Aug 2016  | Viewed:98236  | Downloaded:217
    +HTML| PDF
  • Review|Open Access

    Hepatitis B virus molecular biology and pathogenesis

    R. Jason Lamontagne , Sumedha Bagga , Michael J. Bouchard
    As obligate intracellular parasites, viruses need a host cell to provide a milieu favorable to viral replication. Consequently, viruses often adopt mechanisms to subvert host cellular signaling processes. While beneficial for the viral replication cycle, virus-induced deregulation of host cellular signaling processes can be detrimental to host cell physiology and can lead to virus-associated pathogenesis, including, for oncogenic viruses, cell transformation and cancer progression. Included among these oncogenic viruses is the hepatitis B virus (HBV). Despite the availability of an HBV... Read more
    Hepatoma Res 2016;2:163-86. | doi:10.20517/2394-5079.2016.05
    Published on: 1 Jul 2016  | Viewed:45881  | Downloaded:1122
    +HTML| PDF
  • Review|Open Access

    Radiological diagnosis of hepatocellular carcinoma in non-cirrhotic patients

    Alba Castán , Ylenia Navarro , Luis Sarría , Raquel Larrosa , Mario Serradilla , Alejandro Serrablo
    Hepatocellular carcinoma (HCC) arising in non-cirrhotic livers is relatively rare. Compared with HCC arising in cirrhotic livers they have some quirks. HCC in healthy livers are large tumors at diagnosis, and are detected due to the onset of abdominal symptoms, outside of any scheduled monitoring program. In non-cirrhotic patients, HCC has the same appearance as the classic image of cirrhotic HCC substrate. The presence of capsule, extensive intratumoral necrosis and typical behavior in the dynamic study after administration of intravenous contrast are present in most of the non-cirrhotic... Read more
    Hepatoma Res 2017;3:1-17. | doi:10.20517/2394-5079.2015.62
    Published on: 12 Jan 2017  | Viewed:12615  | Downloaded:331
    +HTML| PDF
  • Review|Open Access

    Diet and nutrition therapy in pre-liver transplant patients

    Neha Bakshi , Kalyani Singh
    Malnutrition is universally prevalent among pre-liver transplantation patients. Malnutrition among cirrhotic patients had been associated to increased morbidity and mortality rates. Also, severely malnourished patients before the transplant surgery have a higher rate of complications and a decreased overall survival rate after liver transplantation. In light of the high incidence of malnutrition and associated complications, it is essential to initiate treatment as early as it is assessed. This review addresses the aetiologies of malnutrition and appropriate treatment strategies to correct... Read more
    Hepatoma Res 2016;2:207-15. | doi:10.20517/2394-5079.2016.02
    Published on: 5 Aug 2016  | Viewed:9938  | Downloaded:316
    +HTML| PDF
  • Review|Open Access

    Management of advanced hepatocellular carcinoma: review of current and potential therapies

    Asmaa Gomaa , Imam Waked
    Over the past few years, despite improvement in screening and diagnosis of hepatocellular carcinoma (HCC), advanced stage remains the most common presentation at diagnosis, with limited management options, especially options available to patients in limited resource countries. There is currently no effective systemic chemotherapy, targeted, or immunologic therapy for advanced stage HCC. Sorafenib is the only approved front-line molecular-targeted treatment,with slight survival benefit. Regorafenib has recently been approved as second line therapy for HCC after failure of sorafenib. Ongoing... Read more
    Hepatoma Res 2017;3:112-22. | doi:10.20517/2394-5079.2017.03
    Published on: 15 Jun 2017  | Viewed:6836  | Downloaded:658
    +HTML| PDF
  • Minireview|Open Access

    Updates on hepatorenal syndrome and strategies bridging to liver transplantation

    Chung Yeung Cheung , Kenneth S.H. Chok
    Hepatorenal syndrome is not an uncommon life-threatening complication arising from liver cirrhosis. The diagnostic criteria for this syndrome have been revised throughout the years, with recent revisions aimed at improving earlier diagnosis and treatment. Liver transplantation remains the only definitive treatment for hepatorenal syndrome. Due to the scarcity of liver grafts, many patients die waiting. This review focuses on the different strategies to bridge patients to liver transplantation and to improve the postoperative outcome. Read more
    Hepatoma Res 2017;3:67-72. | doi:10.20517/2394-5079.2016.48
    Published on: 12 Apr 2017  | Viewed:6682  | Downloaded:493
    +HTML| PDF
  • Topic: Advances in the diagnosis and treatment of liver fibrosis|Open Access

    Advances in the diagnosis and treatment of liver fibrosis

    Jenny Yeuk-Ki Cheng , Grace Lai-Hung Wong
    Liver fibrosis is the center of diagnosis and management of essentially all chronic liver diseases. While liver biopsy examination still has a role in diagnosis and drug development, it is replaced by non-invasive assessments of liver biopsy in majority of the clinical scenarios. Radiological approaches, namely transient elastography, acoustic radiation force impulse imaging, shear wave elastography, magnetic resonance elastography provide accurate diagnosis of advanced fibrosis and cirrhosis. Serum test formulae based on common laboratory parameters or more specialized parameters including... Read more
    Hepatoma Res 2017;3:156-69. | doi:10.20517/2394-5079.2017.27
    Published on: 8 Aug 2017  | Viewed:5091  | Downloaded:321
    +HTML| PDF
  • Original Article|Open Access

    In vitro antitumor efficacy of Kochia indica extract on human hepatocellular carcinoma cell line with or without 5-fluorouracil

    Nabil Mohie Abdel-Hamid , Ghada A. Tabl , Yousry E. El-Bolkiny , Walaa O. Zeina
    Aim: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the sixth most common cancer worldwide. The resistance to chemotherapy is a major obstacle in the treatment of HCC, necessitating the discovery of additional agents. There is a growing use of anticancer complementary and alternative medicine worldwide. Therefore, the aim of present study was focused on the confirmation of the suitability and validity of the new markers which would be achieved by demonstrating their significant change and reproducible expression during disease and disease management. Methods:... Read more
    Hepatoma Res 2017;3:149-55. | doi:10.20517/2394-5079.2016.50
    Published on: 21 Jul 2017  | Viewed:4200  | Downloaded:137
    +HTML| PDF
  • Review|Open Access

    Percutaneous hepatic perfusion with melphalan for unresectable liver metastasis

    Humair S. Quadri , Eden C. Payabyab , David J. Chen , William Figg , Marybeth S. Hughes
    Percutaneous hepatic perfusion (PHP) is an investigative technique for treating patients with diffuse unresectable metastatic liver disease. The technique has been clinically evaluated and shows great treatment potential for regional therapy to the liver. The advantage of PHP lies in its minimally invasive approach and ability to be repeated when compared to isolated hepatic perfusion. In a literature search, 135 publications were screened and 16 of these publications, including clinical trials and reviews, contributed to this review of PHP with melphalan. Melphalan is an alkylating agent... Read more
    Hepatoma Res 2016;2:197-202. | doi:10.20517/2394-5079.2016.24
    Published on: 13 Jul 2016  | Viewed:4149  | Downloaded:200
    +HTML| PDF
  • Original Article|Open Access

    Preoperative liver functional volumetry performed by 3D-99mTc-GSA scintigraphy/vascular fusion imaging using SYNAPSE VINCENT: a preliminary study

    Hiroshi Yoshida , Hiroshi Makino , Tadashi Yokoyama , Hiroshi Maruyama , Atsushi Hirakata , Junji Ueda , Yasuhiro Mamada , Nobuhiko Taniai , Eiji Uchida
    Aim: The present study was designed to evaluate the feasibility of preoperative liver functional volumetry performed by 3D-technetium-99m-diethylenetriaminepentaacetic acid-galactosyl-human serum albumin (99mTc-GSA) scintigraphy/vascular fusion imaging using SYNAPSE VINCENT and to examine the discrepancy between conventional and functional volumetry. Methods: The study group comprised 15 patients who underwent preoperative 3-dimensional (3D)-99mTc-GSA scintigraphy/vascular fusion imaging using SYNAPSE VINCENT software before hepatectomy between July 2014 and August 2015. The diagnosis was... Read more
    Hepatoma Res 2016;2:187-92. | doi:10.20517/2394-5079.2016.06
    Published on: 1 Jul 2016  | Viewed:4101  | Downloaded:219
    +HTML| PDF
  • Topic: Novel Approaches for HCC|Open Access

    Immunotherapy for hepatocellular carcinoma: the force awakens in HCC?

    Lynn G. Feun , Ying-Ying Li , Medhi Wangpaichitr , Chun-Jing Wu , Niramol Savaraj
    Systemic therapy for hepatocellular carcinoma (HCC) has been disappointing. The only drug approved by Food and Drug Administration recently has been sorafenib. Sorafenib has modest benefits with a low response rate and an improvement in time to progression of only 2-3 months. Multiple randomized trials, which compare the new agent to sorafenib as either first line or second line therapy, have been negative, showing no improved clinical benefit. Recently, in a large phase III randomized trial, regorafenib has shown superiority to placebo as a second line treatment for HCC. However, this drug... Read more
    Hepatoma Res 2017;3:43-51. | doi:10.20517/2394-5079.2016.45
    Published on: 22 Mar 2017  | Viewed:4020  | Downloaded:908
    +HTML| PDF
  • Commentary|Open Access

    Comment on “Preliminary outcome of microwave ablation of hepatocellular carcinoma: breaking the 3-cm barrier?”

    Paola Tombesi , Francesca Di Vece , Francesca Ermili , Sergio Sartori
    Hepatoma Res 2016;2:237-8. | doi:10.20517/2394-5079.2016.30
    Published on: 25 Aug 2016  | Viewed:3752  | Downloaded:124
    +HTML| PDF
  • Original Article|Open Access

    Evaluating normalization approaches for the better identification of aberrant microRNAs associated with hepatocellular carcinoma

    Jing Shen , Qiao Wang , Irina Gurvich , Helen Remotti , Regina M. Santella
    Aim: Dysregulated microRNAs (miRNAs) have been identified in hepatocellular carcinoma (HCC), but only a small proportion have been confirmed. An appropriate normalizer is crucial to determining the accuracy and reliability of data from miRNA studies. Methods: Different normalization strategies were used to validate genome-wide miRNA profiles in HCC tumor and non-tumor tissues, and to determine the consistency and discrepancy of data on dysregulated miRNAs. Results: Two sets of stable miRNAs (miR-30c/miR-30b and miR-30c/miR-126) were identified in HCC tissues by geNorm and NormFinder tools,... Read more
    Hepatoma Res 2016;2:305-15. | doi:10.20517/2394-5079.2016.28
    Published on: 18 Nov 2016  | Viewed:3523  | Downloaded:188
    +HTML| PDF
  • Topic: Advances in Minimally Invasive Cirrhotic Surgery|Open Access

    Case report of the fourth laparoscopic liver resection and review of repeat laparoscopic resection for recurrent hepatocellular carcinoma in cirrhotic liver

    Zenichi Morise , Masashi Isetani , Norihiko Kawabe Norihiko Kawabe , Hirokazu Tomishige , Hidetoshi Nagata , Satoshi Arakawa , Masahiro Ikeda , Kenshiro Kamio
    A 73-year-old woman with liver cirrhosis caused by hepatitis C virus (HCV) underwent treatment of three hepatocellular carcinomas (HCCs) in liver segment 4, following three previous laparoscopic liver resections (LLRs) over 73 months. Contrast-enhanced computed tomography showed three 0.5-1.2 cm HCCs deep within the portal territories of subsegments 4a and 4b. The patient underwent laparoscopic resection of 4a and 4b, with the preservation of the portal branch to 4c, after minimal adhesiolysis around segment 4. The operation lasted 284 min, there was 50 mL of intra-operative bleeding and... Read more
    Hepatoma Res 2016;2:253-8. | doi:10.20517/2394-5079.2016.09
    Published on: 19 Sep 2016  | Viewed:3209  | Downloaded:133
    +HTML| PDF
  • Viewpoint of Editor-in-Chief|Open Access

    Cancer Evo-Dev, a novel hypothesis derived from studies on hepatitis B virus-induced carcinogenesis

    Guang-Wen Cao
    Non-resolving inflammation, which may be maintained by infection, pollution, and metabolic stimulants and their interactions with immunogenetic predisposition, provides a fertile field for cancer development. This is strongly evident in hepatocellular carcinoma. Here, the framework of a hypothesis called Cancer Evo-Dev is presented, based on the advances in hepatitis B virus-induced hepatocarcinogenesis. Several aspects central to this theory are as follows: (1) immune imbalance caused by the interaction of immunogenetic predispositions and hepatitis B virus infection maintains... Read more
    Hepatoma Res 2017;3:241-59. | doi:10.20517/2394-5079.2017.45
    Published on: 27 Oct 2017  | Viewed:3181  | Downloaded:148
    +HTML| PDF
  • Case Report|Open Access

    An extra-adrenal pheochromocytoma mimicking a primary liver cancer

    Kenneth Siu Ho Chok , Florence Loong , Chung Mau Lo
    Despite doctors’ every effort to be vigilant when diagnosing, sometimes a preoperative diagnosis is disproved by postoperative pathological examination. A patient was diagnosed with hepatocellular carcinoma and received surgery as treatment. On operation, a solitary retroperitoneal mass rather than a liver lesion was seen. On histopathological examination, the retroperitoneal mass was found to be an extra-adrenal pheochromocytoma. Read more
    Hepatoma Res 2016;2:297-9. | doi:10.20517/2394-5079.2016.04
    Published on: 7 Nov 2016  | Viewed:3039  | Downloaded:112
    +HTML| PDF
  • Original Article|Open Access

    Is transarterial embolization a valuable treatment option for spontaneous rupture of hepatocellular carcinoma: experience from a tertiary care hospital of South-Asia

    Amna Subhan Butt , Saeed Hamid , Nazish Butt , Fatima Sharif , Tanveer Ul Haq , Wasim Jafri
    Aim: Transarterial embolization (TAE) has been found beneficial in treatment of ruptured Hepatocellular carcinoma (HCC) in earlier studies. So far no data is available from Pakistan. The aim of this study was to evaluate clinicopathological characteristics, outcomes of patients presented with spontaneously ruptured, unresectable HCC treated with or without TAE and to evaluate the factors associated with 30-day mortality. Methods: This was a cross sectional study. Patients ≥ 18 years old, presented with spontaneous rupture of unresectable HCC, were evaluated. The outcome measures were... Read more
    Hepatoma Res 2016;2:279-86. | doi:10.20517/2394-5079.2016.08
    Published on: 21 Oct 2016  | Viewed:2961  | Downloaded:208
    +HTML| PDF
  • Case Report|Open Access

    Aggressive primary hepatic histiocytic sarcoma: case report and literature review

    Guang Yang , Jeremy Deisch , Haixia Qin , Craig Zuppan , Anwar S. Raza
    Histiocytic sarcoma is an uncommon non-Langerhans histiocyte disorder of mature tissue histiocytes. The authors presented an example of this rare tumor in a 14-year-old girl who presented with left upper quadrant pain, loss of appetite, and weight loss. A large 18 cm × 10 cm heterogeneous solid and cystic enhancing mass was found in the left lobe of the liver. Based on the histomorphology and positivity for histiocyte-specific markers in a needle biopsy, a diagnosis of histiocytic sarcoma was made. Chemotherapy was initiated, but the tumor did not respond well, and she died about 7 weeks... Read more
    Hepatoma Res 2016;2:300-4. | doi:10.20517/2394-5079.2016.10
    Published on: 7 Nov 2016  | Viewed:2914  | Downloaded:97
    +HTML| PDF
  • Case Report|Open Access

    Hemorrhagic cardiac tamponade after percutaneous laser ablation of a liver metastasis in segment II

    Paola Tombesi , Francesca Di Vece , Silvia Rinaldi , Matteo Bertini , Sergio Sartori
    Despite percutaneous laser thermal ablation (LTA) of liver tumors being regarded as a safe technique, major complications can occur. We report the first case of hemorrhagic cardiac tamponade after LTA of a colorectal metastasis in segment II of the liver. Unpredictable heat diffusion causing indirect thermal injury to the pericardium with resultant hemorrhagic reaction was hypothesized as the most likely cause of tamponade. A pericardial drain was emergently placed, 200 mL of bright red blood were drained, and the patient showed rapid hemodynamic improvement. For lesions located in segment... Read more
    Hepatoma Res 2016;2:193-6. | doi:10.20517/2394-5079.2015.68
    Published on: 1 Jul 2016  | Viewed:2766  | Downloaded:106
    +HTML| PDF
  • Review|Open Access

    Novel predictive and prognostic strategies of hepatitis B virus related hepatocellular carcinoma

    Wen-Bin Liu , Fan Yang , Ding-Yi Shao , Guang-Wen Cao
    Hepatocellular carcinoma (HCC) is a common malignancy and an important cause of cancer death worldwide. Chronic hepatitis B virus (HBV) infection is the major cause of HCC. Recent studies of HBV-induced carcinogenesis not only discovered many new biomarkers but also developed a novel theory: Cancer Evolution-Development (Cancer Evo-Dev). Cancer Evo-Dev provides an evolutionary insight of developing more reasonable predictive and prognostic strategies. Characterizing chronic inflammatory microenvironment of cancer evolution, genetic polymorphisms of inflammatory factors, and HCC-related HBV... Read more
    Hepatoma Res 2016;2:331-40. | doi:10.20517/2394-5079.2016.38
    Published on: 23 Dec 2016  | Viewed:2762  | Downloaded:171
    +HTML| PDF
  • Original Article|Open Access

    Clinical and molecular sub-classification of hepatocellular carcinoma relative to alpha-fetoprotein level in an Asia-Pacific island cohort

    Scott T. Nishioka , Miles M. Sato , Linda L. Wong , Maarit Tiirikainen , Sandi A. Kwee
    Aim: Increased serum alpha-fetoprotein (AFP) levels are associated with specific molecular sub-classes of hepatocellular carcinoma (HCC), supporting AFP as a predictive or therapeutic biomarker for precision treatment of this disease. Considering recent efforts to validate HCC molecular classification systems across different populations, we applied existing signature-based classification templates to Hawaii cohorts and examined whether associations between HCC molecular sub-class, AFP levels, and clinical features found elsewhere can also be found in Hawaii, a region with a unique... Read more
    Hepatoma Res 2018;4:1. | doi:10.20517/2394-5079.2017.46
    Published on: 12 Jan 2018  | Viewed:2715  | Downloaded:115
    +HTML| PDF
  • Topic: Advances in Minimally Invasive Cirrhotic Surgery|Open Access

    Indications and technique for laparoscopic liver resection in patients with hepatocellular carcinoma and liver cirrhosis

    Yuichiro Otsuka , Masaru Tsichiya , Toshio Katagiri , Yoshihisa Kubota , Jun Ishii , Tetsuya Maeda , Hironori Kaneko
    Liver resection is the preferred initial treatment option for solitary or limited multifocal hepatocellular carcinoma (HCC). However, because of the characteristics of HCC, including its high recurrence rate and the frequent presence of chronic hepatitis and cirrhosis, both curability and invasiveness must be considered when selecting a treatment for HCC. Laparoscopic liver resection (LLR) is minimally invasive and increasingly performed worldwide as a curative surgical option for treatment of liver tumors. The 2014 International Consensus Conference on LLR concluded that minor LLRs are now... Read more
    Hepatoma Res 2016;2:241-7. | doi:10.20517/2394-5079.2016.11
    Published on: 19 Sep 2016  | Viewed:2670  | Downloaded:196
    +HTML| PDF
  • Review|Open Access

    Reducing liver cancer risk beginning at birth: experiences of preventing chronic hepatitis B virus infection in China

    Chunfeng Qu , Zhongping Duan , Kun Chen , Huaibin Zou
    In China, the death numbers due to primary liver cancer every year account for more than half of this disease burden worldwide. Hepatocellular carcinoma (HCC) represents the major histological type of primary liver cancer. In the Chinese population, at least 85% HCC cases are due to chronic infection with hepatitis B virus (HBV), most of which were acquired in the perinatal period or in early life. As of January 1992, HBV immunization of newborns was introduced to the national Expended Program of Immunization of China. Prior to this program, the Qidong County in China conducted an hepatitis... Read more
    Hepatoma Res 2017;3:228-40. | doi:10.20517/2394-5079.2017.41
    Published on: 25 Oct 2017  | Viewed:2662  | Downloaded:98
    +HTML| PDF
  • Original Article|Open Access

    Late recurrence of hepatocellular carcinoma after liver transplantation

    Julia A. Zhang , Sandi A. Kwee , Linda L. Wong
    Aim: Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and liver transplant (LT) prolongs survival. However, 15-20% will experience recurrent HCC, most occurring within 2 years of LT. HCC patients with late recurrences (> 5 years after LT) may have distinctive clinical/biological characteristics. Methods: A retrospective review was conducted of 88 patients who underwent LT for HCC during 1993-2015, analyzing demographics, clinical factors, explant pathology, and outcome. Results: Median follow-up was 6.4 years. HCC recurred in 15 (17.0%) patients with... Read more
    Hepatoma Res 2017;3:58-66. | doi:10.20517/2394-5079.2017.05
    Published on: 10 Apr 2017  | Viewed:2621  | Downloaded:182
    +HTML| PDF
  • Original Article|Open Access

    Detecting hepatic nodules and identifying feeding arteries of hepatocellular carcinoma: efficacy of cone-beam computed tomography in transcatheter arterial chemoembolization

    Yasuhiro Ushijima , Tsuyoshi Tajima , Akihiro Nishie , Yoshiki Asayama , Kousei Ishigami , Masakazu Hirakawa , Daisuke Kakihara , Daisuke Okamoto , Hiroshi Honda
    Aim: To evaluate the effectiveness of using cone-beam computed tomography (CBCT) in transcatheter arterial chemoembolization (TACE) to detect hapatocellular carcinoma (HCC) nodules and their feeding arteries. Methods: Twenty-four patients with HCCs who underwent TACE using CBCT in addition to conventional digital subtraction angiography (DSA) were enrolled. After both conventional DSA and CBCT through the hepatic artery were acquired, TACE were performed. The nodules were defined as an HCC when dense accumulation of iodized oil was found within the nodule on CT obtained 2 weeks after the... Read more
    Hepatoma Res 2016;2:231-6. | doi:10.20517/2394-5079.2016.32
    Published on: 25 Aug 2016  | Viewed:2612  | Downloaded:145
    +HTML| PDF
  • Editorial|Open Access

    Liver transplantation in acute-on-chronic liver failure

    Roger Williams
    Hepatoma Res 2017;3:90-4. | doi:10.20517/2394-5079.2017.13
    Published on: 17 May 2017  | Viewed:2510  | Downloaded:169
    +HTML| PDF
  • Brief Communication|Open Access

    Hepatic disorder in Zika virus infection

    Viroj Wiwanitkit
    Zika virus infection is the present global problem. This arbovirus infection can cause acute illness and affect fetus in utero. However, there can be other additional clinical manifestation including to the hepatic disorder. In this short commentary article, the author briefly discusses on the liver problem due to Zika virus infection. Read more
    Hepatoma Res 2016;2:203-4. | doi:10.20517/2394-5079.2016.17
    Published on: 13 Jul 2016  | Viewed:2476  | Downloaded:314
    +HTML| PDF
  • Review|Open Access

    Direct antiviral therapy for hepatitis C and hepatocellular carcinoma: facing the conundrum

    Federica Buonfiglioli , Stefano Brillanti
    Direct antiviral therapy has dramatically changed our possibility to eradicate hepatitis C virus (HCV) infection in all stages of chronic liver disease, with sustained virological response rates well above 90%. HCV eradication should lead to a better prognosis even after cirrhosis has established, including a reduced risk of developing hepatocellular carcinoma (HCC). Unfortunately, during the last two years different reports have raised the concern about a possible increased risk of developing HCC in cirrhotic patients treated with direct antivirals. In this review, we have evaluated the... Read more
    Hepatoma Res 2018;4:6. | doi:10.20517/2394-5079.2017.42
    Published on: 10 Feb 2018  | Viewed:2396  | Downloaded:164
    +HTML| PDF
  • Original Article|Open Access

    Antioxidant activity and free radical-scavenging of cape gooseberry (Physalis peruviana L.) in hepatocellular carcinoma rats model

    Hanaa A. Hassan , Nermin E. Ghareb , Ghassan F. Azhari
    Aim: Oxidative damage of cellular components by free radicals and other reactive oxygen molecules is believed to be associated with the development of degenerative diseases. The aim of the present study was to evaluate the antioxidant capacity and free radical scavenging activity of cape gooseberry juice (CGJ) in diethylnitrosamine-(DENA) and CCl4 (3 mL/kg b.w.)-induced hepatocellular carcinoma (HCC) rats model. Methods: The rats were divided into 4 groups (6 rats each group). Group 1 (control): the rats of this group did not receive any treatments; group 2 (CGJ): rats were daily... Read more
    Hepatoma Res 2017;3:27-33. | doi:10.20517/2394-5079.2016.33
    Published on: 28 Feb 2017  | Viewed:2386  | Downloaded:177
    +HTML| PDF
  • Original Article|Open Access

    Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma

    Hie-Won Hann , Surbhi Jain , Grace Park , Jamin D. Steffen , Wei Song , Ying-Hsiu Su
    Aim: This study aimed to explore the potential of detecting hepatocellular carcinoma (HCC)-associated DNA markers, TP53 249T mutations and aberrant methylation of RASSF1A and GSTP1 genes, for monitoring HCC recurrence. HCC remains a leading cause of death worldwide, with one of the fastest growing incidence rates in the US. While treatment options are available and new ones emerging, there remains a poor prognosis of this disease mostly due to its late diagnosis and high recurrence rate. Although there are no specific guidelines addressing how HCC recurrence should be monitored, recurrence... Read more
    Hepatoma Res 2017;3:105-11. | doi:10.20517/2394-5079.2017.15
    Published on: 6 Jun 2017  | Viewed:2379  | Downloaded:214
    +HTML| PDF
  • Original Article|Open Access

    Laparoscopic liver resection with lymph node dissection for gallbladder tumors suspected to be T1b/T2 carcinoma

    Masashi Isetani , Zenichi Morise , Akihiko Horiguchi
    Aim: The short-term perioperative results of laparoscopic treatment of gallbladder (GB) carcinoma were evaluated to determine whether this technique can be a feasible treatment option. Methods: Ten patients with fundus/body GB tumors (GBTs) underwent laparoscopic liver resection (LLR) and lymph node dissection. Additionally, 124 patients underwent LLR for liver tumors. These 124 LLRs included 79 partial resections (PRs), 11 left lateral sectionectomies (LLSs), 25 anatomical resections (ARs), and 9 small ARs (SARs). The operation time (OT), intraoperative blood loss (BL), and postoperative... Read more
    Hepatoma Res 2017;3:170-7. | doi:10.20517/2394-5079.2017.17
    Published on: 9 Aug 2017  | Viewed:2298  | Downloaded:83
    +HTML| PDF
  • Original Article|Open Access

    Efficacy of sorafenib therapy in patients with advanced hepatocellular carcinoma in Indian population

    Alit Abraham , Charumathi Purushothaman , Dhanya Damien , Jackson James , Prudence Attilade Rodrigues , Gursharan Singh
    Aim: Hepatocellular carcinoma (HCC) is the fourth most common type of cancer and the third leading cause of cancer-related mortality. Sorafenib is an oral multikinase inhibitor that is used for unresectable advanced HCC. It is only approved systemic therapy for advanced HCC. Methods: A retrospective prospective study conducted in a multispeciality hospital with 50 patients who received sorafenib. The primary outcome of the study was to find out the survival rate of patients treated with sorafenib. The secondary outcome of the study was to explore the efficacy and safety of sorafenib in a... Read more
    Hepatoma Res 2016;2:224-8. | doi:10.20517/2394-5079.2016.03
    Published on: 5 Aug 2016  | Viewed:2280  | Downloaded:162
    +HTML| PDF
  • Topic: Advances in Minimally Invasive Cirrhotic Surgery|Open Access

    Laparoscopic resection of hepatocellular carcinoma in patients with and without cirrhosis: the Brisbane experience

    Daniel J. Kilburn , Universe Leung , David J. Cavallucci , Cassandra Jeavons , Mehan Siriwardhane , Richard Bryant , Thomas R. O’Rourke , Shinn Yeung , Nicholas A. O’Rourke
    Aim: Laparoscopic liver resection for hepatocellular carcinoma (HCC) is increasingly common around the world. There may be significant advantages over open resections. However, due to technical difficulties, they are performed in few centers with expertise in liver and advanced laparoscopic surgery. In this study the authors summarize the experience to date. Methods: A retrospective analysis of consecutive patients undergoing laparoscopic liver resection for HCC in 2 tertiary academic hepatobiliary units in Brisbane, Australia, between 1999 and 2015 was performed. Operative characteristics,... Read more
    Hepatoma Res 2016;2:264-70. | doi:10.20517/2394-5079.2016.29
    Published on: 30 Sep 2016  | Viewed:2269  | Downloaded:150
    +HTML| PDF
  • Original Article|Open Access

    Role of contrast-enhanced ultrasound in the evaluation of vascularization of hepatocellular carcinoma

    Francesco Loria , Giuseppe Loria , Salvatore Basile , Giuseppe Crea , Luciano Frosina , Francesca Frosina
    Aim: Early individualization of hepatocellular carcinoma is crucial to obtain good therapeutic results, thanks to several options such as percutaneous therapies, surgical resections and transplant. Aim of this study is to evaluate the vascularization of hepatocarcinoma using contrast enhanced ultrasound (CEUS) in comparison with multislice computed thomography (MSCT). Methods: Between January 2009 and May 2014, 67 patients affected by hepatocarcinoma, who presented an overall of 92 nodules, were examined and enrolled in the study. Results: There was a significant difference in the... Read more
    Hepatoma Res 2016;2:316-22. | doi:10.20517/2394-5079.2016.27
    Published on: 22 Nov 2016  | Viewed:2245  | Downloaded:143
    +HTML| PDF
  • Original Article|Open Access

    Use of gadobenate dimeglumine dynamic MRI for detection of early hepatocellular carcinoma in atypical hepatic focal lesions

    Mohamed F. El-Gazzar , Mohamed Ahmed Samy Kohla , Mahmoud M. El-Sakhawy , Mohamed M. Husseiny , Reda R. H. Yousef , Safinaz H. El-Shorbagy
    Aim: Gadobenate dimeglumine (multihance) is a contrast medium which can be used not only as an extracellular contrast agent for dynamic imaging of the liver, but also as a liver specific agent for the acquisition of hepatobiliary-phase images which are more helpful in evaluation of small atypical hepatic focal lesions equal or less than 3 cm. The authors tried to evaluate multihance dynamic magnetic resonance imaging (MRI) as a new modality in early detection of hepatocellular carcinoma (HCC). Methods: Thirty cirrhotic patients with small hepatic focal lesions (less than 3 cm in diameter),... Read more
    Hepatoma Res 2017;3:123-8. | doi:10.20517/2394-5079.2017.08
    Published on: 26 Jun 2017  | Viewed:2225  | Downloaded:138
    +HTML| PDF
  • Case Report|Open Access

    Epstein-Barr virus associated secondary hemophagocytic lymphohistiocytosis with an unusual presentation of abdominal compartment syndrome

    Li Lei , Camilla J. Cobb , Jeffrey Cao , Anwar S. Raza
    Hemophagocytic lymphohistiocytosis (HLH) is a cytokine storm syndrome caused by an overactive but ineffective immune reaction. Without prompt diagnosis and treatment, HLH is life-threatening. However, presenting symptoms are often nonspecific, with fatigue and fever being the most common. A high index of suspicion is therefore critical for early diagnosis and timely management. A previously healthy, 65-year-old female who initially presented with fever and abdominal pain developed abdominal compartment syndrome (ACS) requiring decompressive laparotomy on hospital day 6. Intraoperative... Read more
    Hepatoma Res 2016;2:287-92. | doi:10.20517/2394-5079.2016.18
    Published on: 21 Oct 2016  | Viewed:2222  | Downloaded:92
    +HTML| PDF
  • Case Report|Open Access

    Hepatocarcinoma with metastasis to the anterior mediastinum

    Rogério Camargo Pinheiro Alves , Lorena Sagrilo Auer , Lisa Rodrigues da Cunha Saud , Raquel Coris Arrelaro , Aline Carboni Casado , Bruno Gustavo Ferreira , Denis Szjenfeld , Paula Bechara Poletti
    Liver malignancies are the sixth leading cause of cancer worldwide, whereas hepatocellular carcinoma (HCC) is the most frequent histological type of liver cancer. Extrahepatic metastasis, which rarely involves the mediastinum, is associated with poor prognosis. An 80-year-old male presenting with mild diffuse abdominal pain for 4 months, associated with hyporexia, increased abdominal volume, dry cough, and loss of 4 kg in 1 month, sought medical assistance due to hemoptysis and chest pain. Tomographic study revealed HCC with mediastinal metastasis, after which sorafenib therapy was started.... Read more
    Hepatoma Res 2016;2:293-6. | doi:10.20517/2394-5079.2016.01
    Published on: 21 Oct 2016  | Viewed:2188  | Downloaded:157
    +HTML| PDF
  • Cohort Profile|Open Access

    Qidong hepatitis B virus infection cohort: a 25-year prospective study in high risk area of primary liver cancer

    Tao-Yang Chen , Geng-Sun Qian , Chun-Sun Fan , Yan Sun , Jin-Bing Wang , Pei-Xin Lu , Xue-Feng Xue , Yan Wu , Qi-Nan Zhang , Yan Jin , Yi-Qian Wu , Yu Gan , Jian-Quan Lu , Thomas W. Kensler , John D. Groopman , Hong Tu
    Qidong hepatitis B virus (HBV) infection cohort (QBC) is a prospective community-based study designed to investigate causative factors of primary liver cancer (PLC) in Qidong, China, where both PLC and HBV infection are highly endemic. Residents aged 20-65 years, living in seven townships of Qidong, were surveyed using hepatitis B surface antigen (HBsAg) serum test and invited to participate in QBC from June 1991 to December 1991. A total of 852 and 786 participants were enrolled in HBsAg-positive and HBsAg-negative sub-cohorts in May 1992, respectively. All participants were actively... Read more
    Hepatoma Res 2018;4:4. | doi:10.20517/2394-5079.2017.50
    Published on: 26 Jan 2018  | Viewed:2117  | Downloaded:89
    +HTML| PDF
  • Review|Open Access

    Treatment of high-burden hepatocellular carcinoma: an oncologist perspective

    Landon L. Chan , Stephen L. Chan
    Hepatocellular carcinoma (HCC) is recognized as a major global healthcare burden. Although there have been tremendous improvements in cancer screening and treatment, HCC mortality rate remains high. Many patients with HCC present late to medical attention and thus are not candidates for curative treatment. They typically have high tumor burden at presentation showing heterogeneity in anatomical factors and biochemical profile. Despite the relatively poor prognosis for these patients, significant improvements can still be made in survival if the optimal treatment modality is chosen.... Read more
    This article belongs to the Special Issue Management of Huge and Advanced Hepatocellular Carcinoma
    Hepatoma Res 2018;4:5. | doi:10.20517/2394-5079.2017.49
    Published on: 7 Feb 2018  | Viewed:1939  | Downloaded:106
    +HTML| PDF
  • Case Report|Open Access

    Hepatocellular carcinoma following direct anti-viral for hepatitis C treatment: a report of an Egyptian case series

    Eman A. Rewisha , Maha M. Elsabaawy , Omar Elshaarawy , Ayat Abdullah , Dalia M. Elsabaawy , Omkolsoum M. Alhaddad
    Egypt had been vexed by the highest load of chronic hepatitis C in the world. It represents a vast market of the new direct-acting anti-viral drugs (DAAs); effectively treating chronic hepatitis C virus (HCV) infection. Eradication of HCV in Egypt has been challenged by the observed increased diagnosis of hepatocellular carcinoma (HCC) in relation to DAAs therapy. This is the first Egyptian report annotating to a series of sixteen chronic HCV infected cases without a diagnosis of HCC before DAAs therapy and unexpected development of HCC during or after completion of DAAs therapy. Read more
    Hepatoma Res 2017;3:178-81. | doi:10.20517/2394-5079.2017.18
    Published on: 11 Aug 2017  | Viewed:1863  | Downloaded:229
    +HTML| PDF
  • Original Article|Open Access

    Hepatocellular carcinoma in the setting of interferon-free treatment for chronic HCV hepatitis - experience of a single center

    Elena Laura Iliescu , Adriana Mercan-Stanciu , Letitia Toma , Elena Simona Ioanitescu , Radu Dumitru , Daniel Rusie
    Aim: This study aims to analyze the particularities of hepatitis C induced hepatocellular carcinoma (HCC), developed during or after treatment with direct-acting antivirals. Methods: We conducted an observational prospective study on 278 patients, who underwent treatment for hepatitis C related liver cirrhosis and respectively for F3 chronic hepatitis C. Liver status was assessed using biological parameters and imagistic evaluation (ultrasonography, computed tomography scan, magnetic resonance imaging). Results: The follow-up time was 14 months. Before therapy, 69.3% of the cirrhotic... Read more
    Hepatoma Res 2018;4:3. | doi:10.20517/2394-5079.2017.48
    Published on: 18 Jan 2018  | Viewed:1858  | Downloaded:65
    +HTML| PDF
  • Topic: Advances in Minimally Invasive Cirrhotic Surgery|Open Access

    Laparoscopic liver resection for hepatocellular carcinoma in patients with cirrhosis

    Jai Young Cho , Ho-Seong Han
    Hepatocellular carcinoma (HCC) is a common malignant tumor and many cases occur in patients with liver cirrhosis. Although liver transplantation is the most effective treatment option, hepatectomy is still the first curative treatment option because liver transplantation is limited by the donors and high cost. In recent years, laparoscopic liver resection (LLR) has increasingly been performed in patients with liver cirrhosis, and has several advantages over open liver resection. Besides less pain and shorter hospital stay, LLR in patients with liver cirrhosis is also associated with lower... Read more
    Hepatoma Res 2016;2:259-63. | doi:10.20517/2394-5079.2016.13
    Published on: 30 Sep 2016  | Viewed:1737  | Downloaded:145
    +HTML| PDF
  • Review|Open Access

    Roles of p53 in extrinsic factor-induced liver carcinogenesis

    Tim Link , Tomoo Iwakuma
    Liver cancer remains one of the most common human cancers with a high mortality rate. Therapies for hepatocellular carcinoma (HCC) remain ineffective, due to the heterogeneity of HCC with regard to both the etiology and mutation spectrum, as well as its chemotherapy resistant nature; thus surgical resection and liver transplantation remain the gold standard of patient care. The most common etiologies of HCC are extrinsic factors. Humans have multiple defense mechanisms against extrinsic factor-induced carcinogenesis, of which tumor suppressors play crucial roles in preventing normal cells... Read more
    Hepatoma Res 2017;3:95-104. | doi:10.20517/2394-5079.2017.07
    Published on: 6 Jun 2017  | Viewed:1706  | Downloaded:106
    +HTML| PDF
  • Topic: Advances in Minimally Invasive Cirrhotic Surgery|Open Access

    Laparoscopic liver resection in the cirrhotic patient

    Ben Robichaux , Jesse Sulzer , Joseph F. Buell
    Aim: The adoption of laparoscopic liver resection has been expansive in the last 2 decades with the exception of cirrhotic patients. The current study examines the outcomes of our cirrhotic resections to determine the potential limitations of this technique. Methods: Retrospective analysis of 114 cirrhotic patients. Seventy-five (65.8%) laparoscopic resections were compared to 39 open resections. Seventy-six (66.7%) resections in the series were minor resections (less than 3 segments). Surgical approach and extent of resection were analyzed using student’s t test and regression multivariate... Read more
    Hepatoma Res 2016;2:248-52. | doi:10.20517/2394-5079.2016.23
    Published on: 19 Sep 2016  | Viewed:1673  | Downloaded:111
    +HTML| PDF
  • Original Article|Open Access

    Comparison of p53 and prohibitin expression in the spectrum of hepatitis, cirrhosis, and hepatocellular carcinoma

    Lívia Maria Della Porta , Fernando Silva Ramalho , Carlos Augusto Oliveira , Deisy Mara Silva , Marlei Josiele Augusto , Leandra Náira Zambelli Ramalho
    Aim: To investigate the correlation of p53 and prohibitin (PHB) expression in the spectrum of hepatitis, cirrhosis, and human hepatocellular carcinoma (HCC). Methods: Hepatic biopsies from patients with HCC (n = 60), cirrhosis (CIR, n = 30), hepatitis C virus (HCV, n = 30), and normal livers (NL, n = 20) were examined for immunohistochemical expression of RelA/p65, tumor necrosis factor receptor-1 (TNFR1), TNF-related apoptosis-inducing ligand (TRAIL), p53, and PHB. The samples were also analysed by nuclear factor kappa B (NFκB) Southwestern histochemistry and a transferase-mediated... Read more
    Hepatoma Res 2017;3:34-42. | doi:10.20517/2394-5079.2016.39
    Published on: 28 Feb 2017  | Viewed:1648  | Downloaded:108
    +HTML| PDF
  • Topic: Advances in Minimally Invasive Cirrhotic Surgery|Open Access

    Liver resection for hepatocellular carcinoma within a fast-track management: a propensity-score matched analysis between open and laparoscopic approach

    Francesca Ratti , Federica Cipriani , Raffaella Reineke , Marco Catena , Michele Paganelli , Luigi Beretta , Luca Aldrighetti
    Aim: The study was designed to assess the implications of enhanced recovery after surgery (ERAS) approach in patients submitted to open liver resection for hepatocellular carcinoma (HCC) comparing their short term outcome with patients treated by laparoscopic approach, in a case-matched design. Methods: The open-group (n = 60) was matched in a ratio of 1:1 with patients undergoing laparoscopic liver resection for HCC (Lap-group, n = 60), with a matching achieved on a basis of propensity scores including 6 covariates representing patients characteristics and severity of the disease. Primary... Read more
    Hepatoma Res 2016;2:271-8. | doi:10.20517/2394-5079.2016.20
    Published on: 30 Sep 2016  | Viewed:1645  | Downloaded:115
    +HTML| PDF
  • Letter to Editor|Open Access

    Hepatocellular carcinoma and type 2 diabetes mellitus: cytokeratin 8/18 expression in hepatocellular carcinoma and glycogen-storing hepatocytes

    Kunio Takegoshi , Eikichi Okada , Qin Su
    Hepatoma Res 2016;2:229-30. | doi:10.20517/2394-5079.2016.26
    Published on: 5 Aug 2016  | Viewed:1629  | Downloaded:162
    +HTML| PDF
  • Original Article|Open Access

    MELD score and AST-to-platelet ratio index predict long-term survival in patients with a small hepatocellular carcinoma following non-transplant therapies: a pilot study

    Joy Sarkar , Thomas DeLeon , Linda L. Wong
    Aim: Liver transplantation (LT) is the most effective treatment for long-term survival from hepatocellular carcinoma (HCC); however, insufficient donors limit therapy. The authors sought to identify characteristics that predicted long-term survival after non-transplant therapies in patients with small HCC. Methods: In a database of 1,050 HCC patients, the authors identified those with single HCC ≤ 3.0 cm, who underwent hepatic resection (HR, n = 16), radiofrequency ablation (RFA, n = 55), or LT (n = 23) with 5-year follow-up. Overall survival (OS) and odds-ratios (OR) for survival after... Read more
    Hepatoma Res 2017;3:79-85. | doi:10.20517/2394-5079.2017.06
    Published on: 9 May 2017  | Viewed:1610  | Downloaded:119
    +HTML| PDF
  • Case Report|Open Access

    Congenital absence of the portal vein complicated by hepatocellular carcinoma in the liver of an adult woman: review of imaging, literature and management

    Ankit Mehta , Shree R. Venkat , Lorraine Portelance , Lynn G. Feun
    We present a case of absence of the portal vein and Laennec’s cirrhosis in a 51-year-old female who was diagnosed with hepatocellular carcinoma (HCC). Only 101 cases of this malformation of the splanchnic vasculature have been reported of which 4 were reported to have HCC. Patient had disease progression while waiting for a liver transplant. Patient was treated with 3 separate conventional transarterial chemoembolization procedures at an outside hospital. At our institution, radioembolization of the right hepatic lobe was performed. She succumbed to liver insufficiency 8 years after being... Read more
    This article belongs to the Special Issue Novel Approaches for HCC
    Hepatoma Res 2018;4:7. | doi:10.20517/2394-5079.2017.35
    Published on: 27 Feb 2018  | Viewed:1554  | Downloaded:68
    +HTML| PDF
  • Original Article|Open Access

    Effect of obesity on perioperative outcomes after laparoscopic hepatectomy

    Seeyuen J. Lee , Adam Hauch , Erica Kane , Christoper DuCoin , Michael Darden , Geoffrey Parker , Emad Kandil , Joseph F. Buell
    Aim: Laparoscopic hepatectomy is increasing in utilization, however the procedure has not been adequately examined in the obese patient. This study aims to analyze the effect of obesity on perioperative outcomes after laparoscopic hepatectomy. Methods: Retrospective analysis of 396 laparoscopic hepatectomies in normal [body mass index (BMI) < 25], overweight (BMI ≥ 25), obese (BMI ≥ 30), and severely obese (BMI ≥ 35) patients using multivariate regression models to determine the risk factors for post-operative complications. Results: Normal BMI (n = 78; 20%), overweight (n = 209; 52%),... Read more
    Hepatoma Res 2016;2:323-7. | doi:10.20517/2394-5079.2016.34
    Published on: 13 Dec 2016  | Viewed:1484  | Downloaded:101
    +HTML| PDF
  • Review|Open Access

    Role of early growth response 1 in liver metabolism and liver cancer

    Nancy Magee , Yuxia Zhang
    The liver is an essential organ for nutrient and drug metabolism - possessing the remarkable ability to sense environmental and metabolic stimuli and provide an optimally adaptive response. Early growth response 1 (Egr1), an immediate early transcriptional factor which acts as a coordinator of the complex response to stress, is induced during liver injury and controls the expression of a wide range of genes involved in metabolism, cell proliferation, and inflammation. In support of an important role of Egr1 in liver injury and repair, deficiency of Egr1 delays liver regeneration process.... Read more
    Hepatoma Res 2017;3:268-77. | doi:10.20517/2394-5079.2017.36
    Published on: 20 Nov 2017  | Viewed:1359  | Downloaded:87
    +HTML| PDF
  • Topic: Management of Huge and Advanced Hepatocellular Carcinoma|Open Access

    Surgical strategy for huge and advanced hepatocellular carcinoma in Hong Kong

    Kenneth S.H. Chok
    In Hong Kong, surgical resection is the core curative treatment for huge and advanced hepatocellular carcinoma (HCC). For tumors measuring 10 cm or above, major hepatectomy is usually required, but a future liver remnant not large enough will preclude the operation. Hypertrophy of future liver remnant is a way to render more patients operable, and measures include portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy. For HCC that has invaded a major vessel, en bloc resection with immediate vessel reconstruction is necessary if thrombectomy... Read more
    Hepatoma Res 2017;3:189-95. | doi:10.20517/2394-5079.2017.33
    Published on: 3 Sep 2017  | Viewed:1340  | Downloaded:128
    +HTML| PDF
  • Commentary|Open Access

    Comments on “The severity of non-alcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota”

    Anna Egresi , Krisztina Hagymási , Gabriella Lengyel
    Hepatoma Res 2016;2:328-30. | doi:10.20517/2394-5079.2016.31
    Published on: 13 Dec 2016  | Viewed:1322  | Downloaded:119
    +HTML| PDF
  • Case Report|Open Access

    Sorafenib from palliative to neoadjuvant chemotherapy in hepatocellular carcinoma with major vascular invasion: experience of two cases

    Naganathan Selvakumar , Sandeep Vohra , Deep Sika Arora , Subash Gupta
    Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the incidence is higher in cirrhosis. Treatment options depend on tumor stage, status of liver function, and the general condition of the patient. Major vascular invasion is a contraindication for liver transplantation. Sorafenib has been found to be useful in association with transarterial chemoembolization as an effective chemotherapeutic agent to prolong survival in inoperable HCCs. Here we describe our experience where sorafenib was used as palliation but later turned out to be a neoadjuvant. Both cases had... Read more
    Hepatoma Res 2017;3:18-21. | doi:10.20517/2394-5079.2016.14
    Published on: 12 Jan 2017  | Viewed:1312  | Downloaded:124
    +HTML| PDF
  • Original Article|Open Access

    Association of serum levels of transforming growth factor β1 with disease severity in patients with hepatocellular carcinoma

    Mohamed Ahmed Samy Kohla , Ahmed Attia , Nehad Darwesh , Manar Obada , Hossam Taha , Marwa F. Youssef
    Aim: Transforming growth factor (TGF) is overexpressed by tumor cells like other proteins and growth factors. TGF-β1 is then activated in the extracellular compartment but is unable to control cell proliferation because of the absence or low level of TGF-β1 receptors on the plasma membrane of malignant hepatocytes. This potential mechanism might interrupt the autocrine regulation loop of TGF-β1 and its blocking effect on cell proliferation. TGF-β1 is a multifunctional cytokine involved in the regulation of growth and differentiation of both normal and transformed cells. This study aimed to... Read more
    Hepatoma Res 2017;3:294-301. | doi:10.20517/2394-5079.2017.40
    Published on: 12 Dec 2017  | Viewed:1308  | Downloaded:90
    +HTML| PDF
  • Review|Open Access

    Further understanding of mechanisms involved in liver cancer chemoresistance

    Oscar Briz , Maria J. Perez , Jose J. G. Marin
    An important limitation for the success of chemotherapy in the treatment of primary liver cancer (hepatocellular carcinoma, hepatoblastoma and cholangiocarcinoma) is the marked efficacy of mechanisms of chemoresistance (MOC). These have been previously classified into five groups depending on whether they result in: a reduced drug uptake or enhanced drug export (MOC-1); poor intracellular activation of prodrugs or higher inactivation of active drugs (MOC-2); changes in the molecular targets that impairs the action of the drug by increasing the activity of the metabolic route to be inhibited... Read more
    Hepatoma Res 2017;3:22-6. | doi:10.20517/2394-5079.2016.22
    Published on: 19 Jan 2017  | Viewed:1256  | Downloaded:239
    +HTML| PDF
  • Original Article|Open Access

    Prediction of post-progression survival in patients with advanced hepatocellular carcinoma treated with sorafenib by using time-dependent changes in clinical characteristics

    Yoshiyuki Wada , Yuko Takami , Hajime Matsushima , Masaki Tateishi , Tomoki Ryu , Munehiro Yoshitomi , Hideki Saitsu
    Aim: Sorafenib has been shown to improve time to tumor progression (TTP) and overall survival (OS) in patients with hepatocellular carcinoma (HCC); however, post-progression survival (PPS) has not been well characterized in these patients. This study aimed to evaluate the predictors of PPS by using time-dependent and dynamic changes in radiologic progression patterns, liver function, and performance status (PS) in patients with advanced HCC receiving sorafenib treatment. Methods: We retrospectively analyzed the clinical characteristics of 128 advanced HCC patients with Child-Pugh scores ≤ 7... Read more
    Hepatoma Res 2018;4:8. | doi:10.20517/2394-5079.2017.39
    Published on: 6 Mar 2018  | Viewed:1240  | Downloaded:90
    +HTML| PDF
  • Minireview|Open Access

    Primary hepatic lymphoma: is it a disease entity?

    Fei Xiong , Yong-Song Guan
    It is now widely accepted that lymphoma is a cancer of the lymphatic cells in the immune system and a type of blood cancer that develops when T or B lymphocytes of the white blood cells display uncontrolled proliferation and cellular immortality. Currently, a number of authors have published case reports or case series in which these lesions are defined as primary hepatic lymphoma. This minireview discusses several aspects of the entity of primary hepatic lymphoma, especially the dilemmas in diagnosis. Read more
    Hepatoma Res 2017;3:73-8. | doi:10.20517/2394-5079.2017.02
    Published on: 9 May 2017  | Viewed:1232  | Downloaded:101
    +HTML| PDF
  • Topic: Management of Huge and Advanced Hepatocellular Carcinoma|Open Access

    Outcomes of emergency and interval hepatectomy for ruptured resectable hepatocellular carcinoma: a single tertiary referral centre experience

    Andrew Kai Yip Fung , Charing Ching Ning Chong , Kit Fai Lee , John Wong , Yue Sun Cheung , Anthony Kwong Wai Fong , Paul Bo San Lai
    Aim: The short and long term outcomes of patients who underwent emergency and interval hepatectomy for ruptured and resectable hepatocellular carcinoma (HCC) were analysed. Methods: The data of patients with ruptured HCC presenting between April 2004 and October 2015 were analysed. Emergency hepatectomy was defined as hepatectomy within 48 h of the clinico-radiological diagnosis of HCC rupture. Results: Thirty patients underwent hepatectomy for ruptured HCC. Nine (30%) patients underwent emergency hepatectomy. The median age was 56 and 54 years (P = 0.13) with a similar gender distribution.... Read more
    Hepatoma Res 2017;3:196-204. | doi:10.20517/2394-5079.2017.23
    Published on: 8 Sep 2017  | Viewed:1211  | Downloaded:94
    +HTML| PDF
  • Original Article|Open Access

    Efficacy and HCC development after DAA therapy for patients with chronic hepatitis C: a single center retrospective cohort study

    Akitoshi Douhara , Hiroyuki Ogawa , Satoshi Nakatani , Takahiro Ozutsumi , Erika Shioyama , Masaaki Yoshikawa , Shigehiko Ueda
    Aim: The development of hepatocellular carcinoma (HCC) is reduced after interferon based treatment in patients with chronic hepatitis C (CHC). A new therapy using direct-acting antiviral agents (DAA) has been widely applied since 2014 for CHC. The purpose of this study is to investigate the efficacy, safety and development of HCC after DAA treatment. Methods: The authors enrolled 33 consecutive patients who were treated with DAA for CHC at the hospital between January 2015 and March 2016. The laboratory data were collected at the start and 24 weeks after DAA therapy. Results: The authors... Read more
    Hepatoma Res 2017;3:215-20. | doi:10.20517/2394-5079.2017.32
    Published on: 17 Oct 2017  | Viewed:1198  | Downloaded:103
    +HTML| PDF
  • Commentary|Open Access

    Comment on "A series of microRNA in the chromosome 14q32.2 maternally imprinted region related to progression of non-alcoholic fatty liver disease in a mouse model”

    Pietro Di Fazio , Thaddeus Till Wissniowski
    Hepatoma Res 2016;2:205-6. | doi:10.20517/2394-5079.2016.19
    Published on: 13 Jul 2016  | Viewed:1178  | Downloaded:106
    +HTML| PDF
  • Original Article|Open Access

    Attenuation of liver stiffness in sorafenib-treated patients with advanced hepatocellular carcinoma

    Chien-Fu Hung , Dong Liu , Tsung-Han Wu , Chao-Wei Lee , Kuang-Tse Pan , Ching-Ting Wang , Hsiu-Ying Chai , Ming-Chin Yu , Yi-Cheng Chen
    Aim: Sorafenib is a multi-tyrosine kinase inhibitor and the standard therapy for advanced hepatocellular carcinoma (HCC). This retrospective study aimed to observe the anti-fibrotic effect of sorafenib in patients with advanced HCC. Methods: Seventeen patients with advanced HCC were recruited. Shear wave velocity (SWV) using acoustic radiation force impulse elastography and non-invasive serum markers for liver fibrosis, such as the aspartate aminotransferase (AST) to alanine aminotransferase ratio (AAR), the AST to platelet ratio index, the fibrosis-4 index and the Lok index, were recorded... Read more
    Hepatoma Res 2017;3:52-7. | doi:10.20517/2394-5079.2016.43
    Published on: 24 Mar 2017  | Viewed:1171  | Downloaded:131
    +HTML| PDF
  • Original Article|Open Access

    Response rates of hepatocellular carcinoma and hepatic colorectal cancer metastases to drug eluting bead regional liver therapy

    Glenn W. Stambo , Deborah Cragan
    Aim: The purpose of this study was to evaluate and compare how hepatocellular carcinoma (HCC) and colorectal metastases respond to LC Bead chemoembolization using doxorubicin and irinotecan. Methods: The authors report their experience with doxorubicin and irinotecan eluting beads to treat 13 patients with primary HCC and 25 patients with colorectal metastases over a 1-year period at a single community based oncology practice. Within the colorectal cancer group they compared irinotecan eluting beads to doxorubicin eluting beads. Results: Nine of the 11 (81.8%) doxorubicin treated HCC... Read more
    Hepatoma Res 2017;3:141-8. | doi:10.20517/2394-5079.2017.12
    Published on: 12 Jul 2017  | Viewed:1168  | Downloaded:111
    +HTML| PDF
  • Topic: Advances in Minimally Invasive Cirrhotic Surgery|Open Access

    Introduction of the special issue: “Advances in Minimally Invasive Cirrhotic Surgery”

    Giulio Belli
    Hepatoma Res 2016;2:239-40. | doi:10.20517/2394-5079.2016.16
    Published on: 19 Sep 2016  | Viewed:1139  | Downloaded:101
    +HTML| PDF
  • Original Article|Open Access

    Neoplastic macrovascular invasion represents an independent risk factor for dismal survival in sorafenib treatment for hepatocellular carcinoma

    Michele Lecchini , Andrea Olivani , Elisabetta Biasini , Raffaele Dalla Valle , Carlo Ferrari , Gabriele Missale , Claudia Schianchi
    Aim: Sorafenib efficacy and safety in advanced hepatocellular carcinoma (HCC) have been demonstrated in two randomized international clinical trials and in clinical practice studies. Because of poor survival advantage, to identify clinical and biological parameters remains an unmet clinical need. Methods: Eighty-four patients treated with sorafenib were evaluated for response to therapy and prognostic factors possibly associated with survival. Results: Median overall survival was 8.5 months. Median duration of therapy was 2.5 months with a median daily dose of 800 mg (IQR 600-800). Dose was... Read more
    Hepatoma Res 2017;3:260-7. | doi:10.20517/2394-5079.2017.44
    Published on: 16 Nov 2017  | Viewed:1125  | Downloaded:73
    +HTML| PDF
  • Topic: Management of Huge and Advanced Hepatocellular Carcinoma|Open Access

    Robotic hepatectomy for hepatocellular carcinoma: a clinical review

    Eric C.H. Lai , Daniel T.M. Chung , Oliver C.Y. Chan , Chung Ngai Tang
    The robotic surgical system was developed to overcome the disadvantages of conventional laparoscopic surgery. The use of robots in liver surgery was not well evaluated. This article aimed at reviewing robotic partial hepatectomy to conventional laparoscopic or open partial hepatectomy in terms of perioperative, oncologic, and healthcare costs for hepatocellular carcinoma (HCC). Studies were identified by searching MEDLINE and PubMed databases for articles from January 2004 to June 2017 using the keywords "laparoscopic hepatectomy", "robotic surgery", "robotic hepatectomy", and... Read more
    Hepatoma Res 2017;3:278-83. | doi:10.20517/2394-5079.2017.37
    Published on: 27 Nov 2017  | Viewed:1114  | Downloaded:59
    +HTML| PDF
  • Original Article|Open Access

    Comparison of outcomes between laparoscopic vs. open liver resection for intermediate stage hepatocellular carcinoma

    Avril David , YoungRok Choi , Ho-Seong Han , Yoo-Seok Yoon , Jai Young Cho
    Aim: The Barcelona Clinic Liver Score (BCLC) currently limits hepatic resection only for small, solitary tumors measuring 2-3 cm with no signs of portal hypertension (PHT) or macrovascular invasion. The aim of this study was to show the benefit of surgical resection, and to compare the peri-operative and long-term outcomes between laparoscopic liver resection (LLR) and open liver resection (OLR) for hepatocellular carcinoma (HCC) classified as intermediate stage (B) under BCLC. Methods: From 2004 to 2013, 49 patients staged as intermediate (BCLC B) and who underwent hepatic resection was... Read more
    This article belongs to the Special Issue Management of Huge and Advanced Hepatocellular Carcinoma
    Hepatoma Res 2018;4:2. | doi:10.20517/2394-5079.2017.51
    Published on: 18 Jan 2018  | Viewed:1109  | Downloaded:69
    +HTML| PDF
  • Original Article|Open Access

    Neoadjuvant hepatic arterial infusion chemotherapy for resectable hepatocellular carcinomas

    Rina Tsutsui , Hiroaki Nagamatsu , Osamu Itano , Akihiro Deguchi , Tsubasa Tsutsumi , Mamoru Hiraki , Naohisa Mizukami , Jun Akiba
    Aim: To evaluate the effect of neoadjuvant hepatic arterial infusion chemotherapy (HAIC) on the survival of patients with resectable hepatocellular carcinoma (HCC). Methods: Between January 2003 and January 2014, 80 patients underwent hepatic resection for HCC. Of these patients, we evaluated 49 patients who met the following inclusion criteria: (1) preserved liver function (Child-Pugh A); (2) resectable HCC (≤ 3 nodules, regardless of the size); and (3) HCC with high-grade malignant potential. Among them, 13 patients underwent neoadjuvant HAIC and curative hepatectomy (treatment group).... Read more
    Hepatoma Res 2018;4:13. | doi:10.20517/2394-5079.2018.20
    Published on: 11 May 2018  | Viewed:988  | Downloaded:39
    +HTML| PDF
  • Case Report|Open Access

    First case report of inflammatory myofibroblastic tumor of peritoneal cavity in a living donor liver transplantation recipient

    Naganathan Selvakumar , Parul Saboti , Sumaid Kaul , Subash Gupta
    Post-transplantation malignancies are well known complications after liver transplantation. Certain malignancies are more common in pediatric recipients than adults. Inflammatory myofibroblastic tumors (IMTs) are reactive neoplasms with miniscule malignant potential. IMTs are more common after hematopoietic stem cell transplantation. However, there is 1 case reported in the literature after deceased donor liver transplantation. The authors describe a case of IMT after living donor liver transplantation. The patient was a 1-year-old girl who underwent living donor liver transplantation... Read more
    Hepatoma Res 2017;3:86-9. | doi:10.20517/2394-5079.2017.01
    Published on: 17 May 2017  | Viewed:953  | Downloaded:90
    +HTML| PDF
  • Review|Open Access

    Function of myeloid cell leukaemia-1 and its regulative relations with hepatocellular carcinoma

    Man Zhu , Yan-Min Zhang
    Hepatocellular carcinoma (HCC) remains a challenging disease with a high recurrence rate after surgery and there is an imminent need to identify new treatments. Currently, adjuvant therapy like chemotherapeutics arises to counteract the malignant trait escaping from apoptosis of tumors induced by overexpressed anti-apoptotic factors in HCC. Myeloid cell leukaemia-1 (Mcl-1) as an anti-apoptotic member of Bcl-2 is highly expressed in diverse human cancers, which contributes to cancer cell survival and the resistance to diverse chemotherapeutic agents. It is confirmed that Mcl-1 protein... Read more
    Hepatoma Res 2017;3:129-40. | doi:10.20517/2394-5079.2017.14
    Published on: 6 Jul 2017  | Viewed:940  | Downloaded:117
    +HTML| PDF
  • Review|Open Access

    Interventional radiology for post-transplant anastomotic complications

    Toshiya Shibata
    The effectiveness of percutaneous interventional radiology for anastomotic stricture in hepatic vein, portal vein, and biliary tract after living donor liver transplantation (LDLT) is described. As a number of patients with LDLT are infants < 10-year-old in the study, the first treatment option was balloon dilatation, not primary stenting. However, stent placement was performed in patients with recurrent, repeated stenosis. Read more
    Hepatoma Res 2017;3:221-7. | doi:10.20517/2394-5079.2017.34
    Published on: 25 Oct 2017  | Viewed:909  | Downloaded:47
    +HTML| PDF
  • Review|Open Access

    Systemic therapies for hepatocellular carcinoma: a recap of the current status

    Petros Giovanis , Manuela De Bona , Fabio Farinati , Andrea Buda , Riccardo Berletti , Fable Zustovich , Simona D’Ippolito , Michele De Boni , Umberto Cillo , Davide Pastorelli
    After decades of frustrating nihilism due to lack of innovative therapeutic solutions, the onco-hepatological community is facing up to important novelties for the treatment of intermediate and advanced stages of liver cancer. Four new drugs have been investigated and resulted in positive data: lenvatinib resulted not inferior to the standard of care sorafenib in first line, regorafenib and cabozantinib demonstrated prolonging survival in patients progressed to sorafenib and nivolumab approved by FDA as option after first-line. Contemporary, the knowledge acquired after ten years’... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:10. | doi:10.20517/2394-5079.2018.21
    Published on: 27 Apr 2018  | Viewed:899  | Downloaded:87
    +HTML| PDF
  • Original Article|Open Access

    Clinical outcomes of direct-acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis

    Estefania Berge , Ana Arencibia , Elena Otón , Luis Cejas , Silvia Acosta , Francisco Pérez
    Aim: The aim was to assess the clinical impact of direct-acting antiviral treatment in patients with compensated hepatitis C virus-related cirrhosis after one year of follow-up. Methods: An observational retrospective study was conducted on 129 consecutive patients with compensated cirrhosis treated in 2015, analyzing the evolution of liver function and the development of hepatocellular carcinoma and clinical decompensations. Results: The median follow-up time was 16 months. Most patients were males (73%), the mean age was 58.1 years and the most frequent genotype was 1b (52.2%). All... Read more
    Hepatoma Res 2017;3:209-14. | doi:10.20517/2394-5079.2017.28
    Published on: 27 Sep 2017  | Viewed:871  | Downloaded:87
    +HTML| PDF
  • Case Report|Open Access

    Total regression of hepatocellular carcinoma bone metastases, after liver transplantation, with sorafenib-everolimus

    Dimitrios Giakoustidis , Athanasios Apostolos Gargavanis , Nikolaos Salveridis , Evangelos Cholongitas , Emmanouil Sinakos , Konstantinos Papapolychroniadis , Vasileios Papanikolaou
    Hepatocellular carcinoma (HCC) represents the 5th commonest malignancy worldwide. Liver transplantation consist a radical and most efficient treatment for HCC. Tumor recurrence or metastases after liver transplantation is not uncommon. Hereby is presented a case of a patient transplanted for alcoholic liver disease and HCC and presented with bone metastases a few months later. Treatment with sorafenib and everolimus showed full regression of the metastases. In conclusion, the point of this report is to advertise a single case of total regression of bone lesions due to HCC recurrence, with... Read more
    Hepatoma Res 2017;3:205-8. | doi:10.20517/2394-5079.2017.29
    Published on: 20 Sep 2017  | Viewed:847  | Downloaded:67
    +HTML| PDF
  • Original Article|Open Access

    Transcatheter arterial chemoembolization in recurrent unresectable hepatocellular carcinoma after orthotopic liver transplantation

    Hasmukh J. Prajapati , Pavan Kavali , Hyun S. Kim
    Aim: To investigate the survivals and efficacy of the doxorubicin drug eluting beads transcatheter arterial chemoembolization (TACE) in patients with recurrent hepatocellular carcinoma (HCC) status post orthotopic liver transplantation. Methods: Consecutive patients with HCC who underwent orthotopic liver transplantation from 2005 to 2012 were reviewed. Patients who developed recurrent HCC after orthotopic liver transplantation and received doxorubicin drug eluting beads TACE therapy were identified and included in the study. Survivals were calculated from the time of 1st doxorubicin drug... Read more
    Hepatoma Res 2017;3:182-8. | doi:10.20517/2394-5079.2017.25
    Published on: 17 Aug 2017  | Viewed:813  | Downloaded:82
    +HTML| PDF
  • Topic: Novel Approaches for HCC|Open Access

    The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

    Walid S. Ayoub , Francis Dailey , Paul Martin , Patricia D. Jones
    Worldwide, hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality. In men, it is the fifth most common cancer and seventh most common in women; HCC is the second highest cause of cancer-related death worldwide. It is less prevalent in the USA and Northern Europe and more prevalent in Eastern and South-Eastern Asia. Over 700,000 cases are diagnosed each year - half of which occur in China - and result in roughly the same number of deaths per year. HCC significantly impairs quality of life and is associated with great costs to society. It is estimated that half of... Read more
    Hepatoma Res 2017;3:302-8. | doi:10.20517/2394-5079.2016.44
    Published on: 20 Dec 2017  | Viewed:759  | Downloaded:82
    +HTML| PDF
  • Original Article|Open Access

    Lycopene treatment stalls the onset of experimentally induced hepatocellular carcinoma: a radioisotopic, physiological and biochemical analysis

    Nisha Bhatia , Baljinder Singh , Ashwani Koul
    Aim: The present study was aimed to determine the modulatory role of lycopene enriched tomato extract (LycT) during initiation of N-nitrosodiethylamine (NDEA) induced hepatocellular carcinoma (HCC). Methods: Female Balb/c mice were divided into 4 groups: control, NDEA (200 mg NDEA/kg b.wt, cumulative dose), LycT (5 mg/kg b.wt, thrice a week) and LycT + NDEA. LycT administration was commenced 2 weeks prior to NDEA administration in LycT + NDEA group. Results: NDEA treatment caused histopathological alterations in hepatic tissue and was associated with enhanced serum levels of inflammatory... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:9. | doi:10.20517/2394-5079.2018.04
    Published on: 27 Mar 2018  | Viewed:733  | Downloaded:23
    +HTML| PDF
  • Topic: Management of Huge and Advanced Hepatocellular Carcinoma|Open Access

    The role of oral antiviral therapy in hepatitis B-related hepatocellular carcinoma

    James Fung , Kenneth S.H. Chok
    Hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) in places where chronic hepatitis B infection is endemic. Oral nucleos(t)ide analog (NA) therapy can reduce the risk of HCC, but cannot completely prevent its development. For HBV-related HCCs, viral inhibition by NAs can preserve or improve liver function, thereby increasing the chance of therapeutic intervention. After surgical resection, NAs can prevent reactivation of HBV, and also reduce the chance of de novo development of HCC in the remnant liver. For those who undergo liver transplantation, NAs are... Read more
    Hepatoma Res 2017;3:284-93. | doi:10.20517/2394-5079.2017.38
    Published on: 27 Nov 2017  | Viewed:724  | Downloaded:59
    +HTML| PDF
  • Original Article|Open Access

    A potential clinical based score in hepatitis C virus cirrhotic patients to exclude small hepatocellular carcinoma

    Denise Cerqueira Paranaguá-Vezozzo , Celso Eduardo Lourenço Matielo , Daniel Ferraz de Campos Mazo , Lucas Souto Nacif , Mario Guimaraes Pessoa , Gleicy Luz Reinoso Pereira , Roque Gabriel Rezende de Lima , Patricia Momoyo Yoshimura Zitelli , Suzane Kioko Ono , Flair José Carrilho
    Aim: Hepatitis C virus (HCV) cirrhosis is an important cause of hepatocellular carcinoma (HCC). This study aimed to identify factors of HCC presence among HCV cirrhotic patients with and without small diameter HCC (≤ 3 cm). Methods: A case control transversal study between 1998 and 2003 including 93 patients: 31 with small diameter HCC and 62 without HCC. Groups were matched by age and gender. Multiple logistic regression analysis using Akaike Information Criteria to estimate the probability of HCC was performed. A model score was generated and bootstrap analysis was performed for internal... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:11. | doi:10.20517/2394-5079.2018.17
    Published on: 27 Apr 2018  | Viewed:703  | Downloaded:50
    +HTML| PDF
  • Review|Open Access

    T cell immunotherapy in hepatitis B virus related hepatocellular carcinoma

    Morteza Hafezi , Antonio Bertoletti , Anthony T. Tan
    Chronic hepatitis B Virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC). While multiple treatment modalities are available, liver transplantation remains the sole curative treatment for advanced stages of HCC, and hence new treatment approaches are required to fulfill this unmet need of curative HCC therapy. Our first-in-man proof-of-concept adoptive T-cell immunotherapy against HBV related hepatocellular carcinoma metastases has shown promising results. Here, we review the development of T-cell immunotherapy targeting HBV antigens for the treatment of HBV-HCC... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:16. | doi:10.20517/2394-5079.2018.55
    Published on: 30 May 2018  | Viewed:569  | Downloaded:31
    +HTML| PDF
  • Review|Open Access

    New strategy to distinguish clonal origin of RHCC/MHCC between intrahepatic metastasis and multicentric occurrence

    Han Wang , Wen-Ming Cong
    Hepatocellular carcinoma (HCC) is a kind of malignancy with high potential of metastasis and multicentric occurrence. The treatment of recurrent hepatocellular carcinoma (RHCC) and multinodular hepatocellular carcinoma (MHCC) is always a nodus because of the diverse clonal origin of RHCC/MHCC. Theoretically, the RHCC/MHCC can originate from intrahepatic metastasis (IM type) or multicentric occurrence (MO type). Our previous study proposed that there are at least 6 subtypes of clonal origin patterns in RHCC. RHCC and MHCC with different clonal origins have variant biological behaviors,... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:14. | doi:10.20517/2394-5079.2018.16
    Published on: 28 May 2018  | Viewed:440  | Downloaded:35
    +HTML| PDF
  • Original Article|Open Access

    Beta2-glycoprotein I cooperate with hepatitis B surface antigen promotes hepatocellular carcinogenesis via the nuclear factor kappa B signal pathway were enhanced by the lipopolysaccharide

    Xue-Li Ding , Xue Jing , Nai-Jun Han , Zi-Bin Tian , Pu-Jun Gao , Lin Yang , Ya-Nan Yu
    Aim: We aimed to elucidate whether beta2-glycoprotein I (β2GPI) cooperation with hepatitis B surface antigen (HBsAg) promoted hepatocellular carcinogenesis enhanced by the lipopolysaccharide (LPS) via activation of nuclear factor kappa B (NF-κB) and expression of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and alpha fetal protein (AFP) in liver cancer cells. Methods: Liver cancer cells (SMMC-7721) were transiently transfected with β2GPI and/or HBsAg and were subjected to LPS treatment. TNF-α, IL-1β, and AFP expression were measured in all groups by ELISA. NF-κB activation was... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:12. | doi:10.20517/2394-5079.2018.07
    Published on: 28 Apr 2018  | Viewed:420  | Downloaded:29
    +HTML| PDF
  • Original Article|Open Access

    Hepatocellular carcinoma in patients without cirrhosis: relevance and clinical characteristics

    Kellyane Santana Dias Carvalho , Luciano E. Fonseca , Helma P. Cotrim
    Aim: The present study evaluated the frequency of hepatocellular carcinoma (HCC) in patients without cirrhosis. Methods: HCC patients were recruited from two reference centers for liver disease in Northeast Brazil from 2010 to 2016. The diagnosis of HCC and cirrhosis was based on international criteria.Results: A total of 169 patients were included, and 16% (27) of the patients did not have hepatocellular carcinoma in non-cirrhosis (HCC-NC). The mean age of HCC-NC was 64.4 ± 11.3 years, and 74.1% of the patients were male. The main risk factors were hepatitis C virus (HCV) in 29.6% (8),... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:15. | doi:10.20517/2394-5079.2018.13
    Published on: 29 May 2018  | Viewed:313  | Downloaded:27
    +HTML| PDF
  • Review|Open Access

    Pre-S2 and HBV associated hepatocellular carcinoma

    Ying Zheng , Yan-Yan Qian , Hong Fan
    Hepatitis B virus (HBV) infection is a primary cause of hepatocellular carcinoma (HCC). Under selection pressures of host immunity and/or immunoprophylaxis and antiviral therapies, HBV evolves by accumulating mutations in its genome. Several studies highlighted the considerable importance of HBV surface (HBs) protein mutants (pre-S/S variants) in tumorigenesis. Among those mutants, pre-S2 mutants have been recognized as “precursor lesions of HCC” and as risk factors for post-operative recurrence of HCC. Pre-S2 mutants play important roles in tumor progression and induce various mechanisms... Read more
    Hepatoma Res 2018;4:17. | doi:10.20517/2394-5079.2018.08
    Published on: 31 May 2018  | Viewed:301  | Downloaded:19
    +HTML| PDF
  • Review|Open Access

    Ablative techniques in hepatocellular carcinoma treatment

    Ehsun Naeem , Shahab Abid
    Hepatocellular carcinoma has been known to arise commonly in the setting of chronic liver disease. Due to its association with cirrhosis, patients with hepatocellular carcinoma often present with markedly diminished hepatic functional reserve, making them poor surgical candidates. For such patients, image-guided percutaneous ablative modalities have provided a viable alternate curative therapy. Although treatment allocation is a decision based on a number of factors, patients eligible for percutaneous ablation generally include those with early stage disease, hepatocellular carcinoma with... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:18. | doi:10.20517/2394-5079.2018.22
    Published on: 13 Jun 2018  | Viewed:105  | Downloaded:12
    +HTML| PDF
  • Review|Open Access

    Mitoepigenetics and hepatocellular carcinoma

    María Guadalupe Lozano-Rosas , Enrique Chávez , Alejandro Rusbel Aparicio-Cadena , Gabriela Velasco-Loyden , Victoria Chagoya de Sánchez
    Mitochondria are the center of energy production in eukaryotic cells and are crucial for several cellular processes. Dysfunctional mitochondria have been associated with cancer progression. Mitochondria contain their own circular DNA (mtDNA), which codes for 13 proteins, 2rRNA, 22tRNA and non-coding RNAs. Recent evidence showed the presence of 5-methylcytosine and 5-hydroximethylcytosine in mtDNA suggesting that the level of gene expression could be modulated like a nuclear DNA by direct epigenetic modifications. Mitoepigenetics is a bidirectional phenomenon in the epigenetic regulation of... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:19. | doi:10.20517/2394-5079.2018.48
    Published on: 19 Jun 2018  | Viewed:64  | Downloaded:11
    +HTML| PDF
  • Review|Open Access

    Intrahepatic cholangiocarcinoma: review and update

    Vincenzo Cardinale , Maria Consiglia Bragazzi , Guido Carpino , Sabina Di Matteo , Diletta Overi , Lorenzo Nevi , Eugenio Gaudio , Domenico Alvaro
    Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies that could develop at any level from the biliary tree. CCA is currently classified into intrahepatic (iCCA), perihilar and distal on the basis of its anatomical location. Of note, these three CCA subtypes have common features but also important inter-tumor and intra-tumor differences that can affect the pathogenesis and outcome. A unique feature of iCCA is that it recognizes as origin tissues, the hepatic parenchyma or large intrahepatic and extrahepatic bile ducts, which are furnished by two distinct stem cell niches, the... Read more
    This article belongs to the Special Issue New Insights in Liver Cancer
    Hepatoma Res 2018;4:20. | doi:10.20517/2394-5079.2018.46
    Published on: 19 Jun 2018  | Viewed:61  | Downloaded:5
    +HTML| PDF
Hepatoma Research ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.